{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:37:32Z","timestamp":1765294652094,"version":"3.37.3"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,5,17]],"date-time":"2014-05-17T00:00:00Z","timestamp":1400284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004321","name":"Shire Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>The safety and efficacy of guanfacine extended release (up to 4\u2009mg\/day) for attention\u2010deficit\/hyperactivity disorder (ADHD) in children and adolescents aged 6\u201317 years is well documented. Data suggest that weight\u2010adjusted doses of guanfacine extended release &gt;0.08\u2009mg\/kg but \u22640.12\u2009mg\/kg, if tolerated, may provide additional clinical benefits. For many adolescents, such dosing would exceed 4\u2009mg\/day, the highest approved dose. This open\u2010label multicenter study evaluated the safety, tolerability, and steady\u2010state pharmacokinetics of guanfacine extended release at escalated forced doses \u22649\u2009mg\/day in adolescents (N\u2009=\u200931) aged 13\u201317 years with ADHD. Following doses of approximately 0.12\u2009mg\/kg, the highest weight group (&gt;70\u201390\u2009kg) exhibited lower mean clearance at steady\u2010state than the lowest weight group (\u226530\u201350\u2009kg). Consistent with its known antihypertensive effects, guanfacine extended release was associated with dose\u2010dependent decreases in blood pressure (BP) and heart rate (HR). The physiologic response of increased BP upon standing was blunted in a dose\u2010related manner while the physiologic response of increased HR upon standing was not substantively affected. The most common treatment\u2010emergent adverse events were somnolence, dizziness, and sinus bradycardia. These results, and those from prior studies, support further examination of the efficacy and safety of higher weight\u2010adjusted doses of guanfacine extended release for ADHD.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cpdd.124","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T09:08:49Z","timestamp":1396084129000},"page":"252-261","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics and pharmacodynamics of guanfacine extended release in adolescents aged 13\u201317 years with attention\u2010deficit\/hyperactivity disorder"],"prefix":"10.1002","volume":"3","author":[{"given":"Patrick","family":"Martin","sequence":"first","affiliation":[{"name":"Shire Development LLC Wayne PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Satin","sequence":"additional","affiliation":[{"name":"Independent Consultant in Cardiac Safety Wellington FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley D.","family":"Vince","sequence":"additional","affiliation":[{"name":"Vince and Associates Clinical Research Overland Park KS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Americo F.","family":"Padilla","sequence":"additional","affiliation":[{"name":"Miami Children's Hospital Miami FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"White","sequence":"additional","affiliation":[{"name":"Shire Pharmaceutical Development Ltd Basingstoke United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Shire Development LLC Wayne PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Shire Development LLC Wayne PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Ermer","sequence":"additional","affiliation":[{"name":"Shire Development LLC Wayne PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199001000-00016"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90716-2"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2007.07161.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00120498"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10641969609088964"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90723-X"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1990.tb01849.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90724-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03068.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.39"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.10.006"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb04900.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0098"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.04.016"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.9.1253"},{"key":"e_1_2_8_17_1","first-page":"49","article-title":"Guanfacine extended release for ADHD","volume":"9","author":"Sallee FR.","year":"2009","journal-title":"Curr Psychiatry."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb04901.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979253283"},{"key":"e_1_2_8_20_1","unstructured":"SatinL MartinP PurkayasthaJ TremblayG.A randomized controlled thorough QT study of guanfacine hydrochloride in healthy adults. Poster presenter at: the 50th Annual Meeting of New Clinical Drug Evaluations (NCDEU); June 14\u201317 2010; Boca Raton FL; 2010."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-3695"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e318191769e"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0152"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900017107"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.020"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0080"},{"issue":"9","key":"e_1_2_8_27_1","first-page":"755","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention\u2010deficit hyperactivity disorder and oppositional symptoms: a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"24","author":"Connor DF","year":"2010","journal-title":"CNS Drugs."}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.124","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T22:43:33Z","timestamp":1696632213000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,17]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1002\/cpdd.124"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.124","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2014,5,17]]}}}